Figure 6 | Scientific Reports

Figure 6

From: In silico and in vivo hepatoprotective activity of the synthesized 5-benzylidene-2-thiohydantoin against diethylnitrosamine-induced liver injury in a rat model

Figure 6

Liver section, IHC HSA -ab. 400×. (A) Placebo group/3 weeks, shows negative staining with HSA antibodies in the cytoplasm of hepatocytes (red arrow). (B) Placebo group/ 6 weeks, shows negative staining with HSA antibodies in the cytoplasm of hepatocytes (red arrow). (C) DEN/3 weeks, shows strong positive staining with HSA antibodies in the affected hepatocytes which stained as cytoplasmic golden brawn granule (red arrow), notice unspecific staining in other hepatocytes (black arrow). (D) DEN group/6 weeks, shows strong positive staining with HSA antibodies in the affected hepatocytes which stained as cytoplasmic golden brawn granule (red arrow). (E) 5B2T group/3 weeks, shows few weakly positive staining with HSA antibodies in the cytoplasm of hepatocytes as golden brown granules (red arrow). (F) 5B2T group/6 weeks, shows few weakly positive staining with HSA antibodies in the cytoplasm of hepatocytes as golden brown granules (red arrow).

Back to article page